ClinicalTrials.gg

Program

Vancomycin

Also written as “Vancomycin inhalation powder”, “vancomycin” and “Vancomycin Hydrochloride for Injection (IA)”.

Its studies are mostly in Cystic Fibrosis · Melanoma · Conjunctivitis, Bacterial · Endocarditis, Bacterial · Cellulitis, led by 4 companies.

Furthest: phase 4, since Dec 11, 20078 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer40 open or runningphase 4since Dec 11, 2007May 3, 2002none ahead
Savara20 open or runningphase 3since Jun 1, 2017Dec 6, 2012none ahead
Kurobe10 open or runningphase 3since Apr 29, 2015Apr 29, 2015none ahead
Osteal Therapeutics10 open or runningphase 2since Oct 17, 2018Oct 17, 2018none ahead

Also a collaborator on its studies: Merck and synteract-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 3, 2002First studies: 2 phase 3 studiesNew to PfizerPfizer · NCT00035425, NCT00037050
  2. Apr 15, 2005Phase 3 study in BacteremiaPfizer · NCT00108433 · 61 enrolled · United States, Colombia, India and more
  3. Dec 11, 2007Phase 4 study in Pneumonia, Ventilator-AssociatedPfizer · NCT00572559 · 149 enrolled · United States, Puerto Rico
  4. Dec 6, 2012Savara's first study: phase 2 study in Cystic FibrosisNew to SavaraSavara · NCT01746095 · 87 enrolled · United States
  5. Apr 29, 2015Kurobe's first study: phase 3 study in Conjunctivitis, BacterialNew to KurobeKurobe · NCT02432807 · 303 enrolled · United States
  6. Jun 1, 2017Phase 3 study in Cystic FibrosisSavara · NCT03181932 · 188 enrolled · United States, Canada
  7. Oct 17, 2018Osteal Therapeutics's first study: phase 2 study in Prosthetic Joint InfectionNew to Osteal TherapeuticsOsteal Therapeutics · NCT03721328 · 15 enrolled · United States

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Peptidoglycan inhibitor; Peptidoglycan inhibitor”ChEMBL 37, by rule

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT03721328Prosthetic Joint Infection · United States2CompletedOsteal TherapeuticsAug 25, 202015
NCT03181932Cystic Fibrosis · United States, Canada3CompletedSavaraJul 28, 2020188
NCT02432807Conjunctivitis, Bacterial · United States3CompletedKurobeMay 31, 2018303
NCT01746095Cystic Fibrosis · United States2CompletedSavaraNov 201487
NCT00572559Pneumonia, Ventilator-Associated · United States, Puerto Rico4CompletedPfizer149
NCT00108433Bacteremia · United States, Colombia, India and more3TerminatedPfizer61
NCT00037050Bacterial Infections3CompletedPfizer739
NCT00035425Febrile Neutropenia · United States, Argentina, Brazil and more3CompletedPfizer120

How it is read

Names in the registry

  • “Vancomycin”, 6 entries
  • “Vancomycin inhalation powder”, 2 entries
  • “vancomycin”, 2 entries
  • “Vancomycin Hydrochloride for Injection (IA)”, 1 entry
  • “Vancomycin Hydrochloride for Injection (IV)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.